Moleculin Biotech (MBRX)
NASDAQ:MBRX
Want to see MBRX full AI Analyst Report?
Top Page
Moleculin Biotech
(NASDAQ:MBRX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▼(-17.36% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by very weak financial performance (no revenue, sizable losses, and heavy ongoing cash burn) alongside bearish technical signals (price below key moving averages and negative MACD). Valuation provides limited support due to negative earnings and no stated dividend yield.
Positive Factors
Strong IP protection for Annamycin
The Hong Kong patent extending protection to 2040 strengthens geographic exclusivity and commercialization optionality in Asia. Durable IP reduces generic substitution risk, supports partner negotiations and market entry plans, and underpins long-term value if clinical success leads to approval.
Negative Factors
Zero revenue with large net losses
The company remains pre-revenue and dependent on successful clinical outcomes to generate sales. Persistent multi-year net losses mean intrinsic economic sustainability hinges on future approvals; absent commercialization, current operations erode equity and leave the business exposed to development risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong IP protection for Annamycin
The Hong Kong patent extending protection to 2040 strengthens geographic exclusivity and commercialization optionality in Asia. Durable IP reduces generic substitution risk, supports partner negotiations and market entry plans, and underpins long-term value if clinical success leads to approval.
Read all positive factors
Moleculin Biotech (MBRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.49M
Dividend YieldN/A
Average Volume (3M)2.74M
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue GrowthN/A
EPS Growth80.65%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-27.96
Shares Outstanding5,336,350
10 Day Avg. Volume1,958,319
30 Day Avg. Volume2,738,732
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.61
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit195.74
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$21.00Price Target Upside767.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-5.11
Revenue Forecast (FY)N/A
Moleculin Biotech Business Overview & Revenue Model
Company Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the tre...
How the Company Makes Money
null...
Moleculin Biotech Earnings Call Summary
Earnings Call Date:May 14, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Aug 19, 2026
Earnings Call Sentiment Positive
The earnings call reflects significant progress in clinical trials and regulatory approvals, particularly for Annamycin. New patents and drug names bolster future market positioning. However, financial constraints and potential EU approval delays pose challenges.Positive Updates
Phase 3 MIRACLE Trial Progress
The Phase 3 MIRACLE trial for Annamycin has officially started with the first patient treated, and 38 sites selected worldwide. The European Medicines Agency has approved the trial in all nine countries requested.
Negative Updates
Financial Runway and Need for Additional Funding
The company ended the quarter with $8 million in cash, which will only run operations into the third quarter of this year, necessitating a $15 million raise.
Read all updates
Q1-2025 Updates
Positive
Negative
Phase 3 MIRACLE Trial Progress
The Phase 3 MIRACLE trial for Annamycin has officially started with the first patient treated, and 38 sites selected worldwide. The European Medicines Agency has approved the trial in all nine countries requested.
Read all positive updates
Company Guidance
During the Moleculin Biotech First Quarter 2025 Update Conference Call, several key metrics and guidance were discussed. The company announced the initiation of the Phase 3 MIRACLE trial for Annamycin, with 38 sites selected globally and the first patient already treated. The European Medicines Agency provided approval for the trial across nine EU countries, marking a significant milestone. Moleculin also revealed additional patent protections for Annamycin, extending its composition of matter protection into at least 2040. They highlighted the progress of their MB-107 clinical trial for advanced soft tissue sarcoma and the investigator-sponsored trial of WP1066, which has recruited seven patients at Northwestern University. Financially, Moleculin ended the quarter with $8 million in cash and anticipates needing to raise approximately $15 million to fund operations into the first quarter of 2026. They aim to unblind data from the first 45 patients in the MIRACLE trial by the end of 2025, which they believe will be pivotal for potential new drug approval. Their market cap stands at over $14 million, with 14.1 million shares outstanding and a three-month average trading volume of nearly 6 million shares per day.Moleculin Biotech Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
54
Neutral
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -37.00K | -90.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -28.89M | -25.01M | -26.52M | -29.50M | -30.51M | -22.80M |
| Net Income | -30.33M | -33.56M | -21.76M | -29.77M | -29.02M | -15.89M |
Balance Sheet | ||||||
| Total Assets | 23.36M | 22.13M | 16.93M | 38.22M | 57.42M | 84.09M |
| Cash, Cash Equivalents and Short-Term Investments | 10.32M | 8.88M | 4.28M | 23.55M | 43.15M | 70.90M |
| Total Debt | 185.00K | 359.00K | 478.00K | 574.00K | 451.00K | 159.00K |
| Total Liabilities | 8.18M | 7.12M | 10.95M | 12.14M | 5.23M | 5.10M |
| Stockholders Equity | 15.18M | 15.01M | 5.98M | 26.07M | 52.19M | 78.99M |
Cash Flow | ||||||
| Free Cash Flow | -24.28M | -22.73M | -23.88M | -24.23M | -27.71M | -18.97M |
| Operating Cash Flow | -24.28M | -22.73M | -23.86M | -24.10M | -27.64M | -18.95M |
| Investing Cash Flow | 0.00 | 0.00 | -13.00K | -124.00K | -67.00K | -19.00K |
| Financing Cash Flow | 26.90M | 27.28M | 4.63M | 4.65M | -23.00K | 74.72M |
Moleculin Biotech Technical Analysis
Neutral
2.42
Price Trends
2.37
Positive
2.99
Negative
6.84
Negative
Market Momentum
-0.06
Positive
50.20
Neutral
67.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MBRX, the sentiment is Neutral. The current price of 2.42 is above the 20-day moving average (MA) of 2.40, above the 50-day MA of 2.37, and below the 200-day MA of 6.84, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 50.20 is Neutral, neither overbought nor oversold. The STOCH value of 67.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MBRX.
Moleculin Biotech Risk Analysis
Moleculin Biotech disclosed 58 risk factors in its most recent earnings report. Moleculin Biotech reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Moleculin Biotech Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $100.78M | -15.27 | -666.47% | ― | -100.00% | 46.40% | |
45 Neutral | $3.93M | >-0.01 | -68.21% | ― | ― | ― | |
42 Neutral | $12.49M | -1.84 | ― | ― | ― | 80.65% | |
42 Neutral | $84.45M | -7.35 | -53.86% | ― | -20.00% | 75.26% |
* Healthcare Sector Average
MBRX
Moleculin Biotech
2.39
-21.10
-89.83%
IBIO
Ibio
1.89
1.10
138.34%
INO
Inovio Pharmaceuticals
1.33
-0.69
-34.16%
AKTX
Akari Therapeutics
5.14
-45.05
-89.76%
LNAI
Lunai Bioworks
0.29
-3.04
-91.30%
Moleculin Biotech Corporate Events
Business Operations and Strategy
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial
Positive
May 13, 2026
On May 13, 2026, Moleculin Biotech reported that it is nearing the first unblinding of data from its pivotal Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine in relapsed or refractory acute myeloid leukemia, with the initial 45-patient unblin...
Business Operations and StrategyProduct-Related Announcements
Moleculin highlights favorable cardiac safety data for Annamycin
Positive
May 12, 2026
On May 12, 2026, Moleculin Biotech announced that an abstract presented at the European Hematology Association 2026 Congress reported a favorable cardiac safety profile for Annamycin, its next-generation anthracycline for relapsed or refractory ac...
Business Operations and StrategyProduct-Related Announcements
Moleculin Secures New Hong Kong Patent for Annamycin
Positive
May 8, 2026
On May 8, 2026, Moleculin Biotech announced it had secured a new Hong Kong patent covering its proprietary method of reconstituting liposomal Annamycin, extending protection through June 25, 2040. The invention, jointly owned with The University o...
Business Operations and StrategyProduct-Related Announcements
Moleculin Highlights Promising Preclinical Data for L-ANN
Positive
Apr 23, 2026
On April 23, 2026, Moleculin Biotech reported new preclinical data at the American Association for Cancer Research Annual Meeting 2026 showing strong activity of its lead drug candidate, liposomal Annamycin (L-ANN), in pancreatic ductal adenocarci...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
Moleculin Biotech Stockholders Approve Warrant Share Issuance
Positive
Apr 15, 2026
At a special meeting of stockholders held on April 15, 2026, Moleculin Biotech, Inc. obtained approval to issue up to 6,367,956 shares of common stock upon the exercise of certain warrants issued on February 20, 2026, enhancing the company’s...
Business Operations and StrategyProduct-Related Announcements
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout
Positive
Mar 23, 2026
On March 23, 2026, Moleculin Biotech announced enrollment of the 45th subject in its pivotal Phase 2B/3 MIRACLE trial of AnnAraC, a combination of Annamycin and cytarabine, for adults with relapsed or refractory acute myeloid leukemia. This marks ...
Business Operations and StrategyRegulatory Filings and Compliance
Moleculin Biotech Updates Investors with New Corporate Presentation
Neutral
Mar 19, 2026
On March 19, 2026, Moleculin Biotech, Inc. reported that it is using a new corporate presentation, which has been posted on its website for stakeholders. The materials were furnished in connection with a Current Report on Form 8-K, underscoring an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.